Nanoform, the medicine performance-enhancing company, announced that it has won a grant of up to 4.3 million euros from Business Finland, the Finnish government organization for innovation funding and trade.

Lantern Pharma is advancing a new ADC program aimed at various solid tumor cancers. The program which uses a cryptophycin-based ADC has already shown very high potency in preclinical tests. 

Bristol Myers Squibb (BMS) has partnered with deep tech company VantAI in a $674 million deal for its Generative AI-driven drug discovery platform.

The European Commission has approved CASGEVY™ (exagamglogene autotemcel) - the first CRISPR/Cas9 gene-edited therapy, for treating severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older.

Latigo Biotherapeutics have just announced $135 million in Series A financing to develop non-opioid medicines for patients suffering from acute and chronic pain​​.

Tirzepatide, Eli Lilly’s weight-loss drug most referred to by its brand names Mounjaro and Zepbound, has shown beneficial effects in relation to weight loss and glucose control. A

Further demonstrating the demand for weight loss drugs, recently published data for Amgen’s experimental obesity drug - MariTide - has shown significant weight loss within acceptable safety profiles in animal and early-stage human trials.

Starting a vegan or ketogenic diet can rapidly alter the immune system, a study reveals. Researchers found that switching to these diets triggers changes in the gut microbiome and immune cell populations within just four weeks.

Nanoform Finland Plc., the medicine performance-enhancing company, announced that one of its leading nanoformulation drug products had received promising relative bioavailability results from its clinical study of nanocrystalline-enabled enzalutamide (nanoenzalutamide) tablet formulation.

Medicine performance-enhancing specialists Nanoform announced it had completed a relative bioavailability study of its nanocrystalline enabled enzalutamide as an alternative to an amorphous solid dispersion formulation of Xtandi®, the leading prescribed androgen receptor inhibitor approved to treat prostate cancer.

To expedite product development and accelerate time-to-market, Colorcon announced its HyperStart C2C™ Smart Formulation Hub, which helps formulators minimize the need for repetitive formulation iterations.